

Louisiana Antibiotic Resistance Testing Summary

October 11, 2023

Condition	Incident Isolates Identified from These Body Sites	Species	Directly Submit to this Laboratory
Carbapenem-resistant Enterobacterales (CRE)	All	All Enterobacterales isolates that are resistant to imipenem, meropenem, doripenem, or ertapenem by standard susceptibility testing methods ¹	LA-OPHL
Carbapenem-resistant <i>Pseudomonas aeruginosa</i> (CRPA)	Sterile Sites Only ²	Non-mucoid <i>Pseudomonas aeruginosa</i> isolates that are resistant to imipenem, meropenem, or doripenem by standard susceptibility testing methods ³	LA-OPHL
Carbapenem-resistant <i>Acinetobacter spp.</i> (CRAB)	All	<i>Acinetobacter spp.</i> isolates that are resistant to imipenem, meropenem, or doripenem by standard susceptibility testing methods ³	LA-OPHL
<i>Candida auris</i>	All	<i>Candida auris</i> , as well as common misidentifications of <i>C. auris</i> (e.g., <i>C. haemolunii</i> , <i>C. duobushaemolunii</i> , <i>C. famata</i> , <i>C. lusitaniae</i> , <i>C. sake</i> , <i>C. parapsilosis</i> , <i>C. catenulata</i> , <i>C. guilliermondii</i> , and <i>Rhodotorula glutinis</i>)	Southeast CDC Antimicrobial Resistance Laboratory
Pan-Non-Susceptible CRE	All	Any CRE isolates identified as <u>intermediate</u> or <u>resistant</u> to all antibiotics tested by the submitting laboratory	LA-OPHL
Pan-Resistant Organisms	All	Any non-mucoid CRPA isolates that are <u>resistant</u> to all drugs tested by submitting laboratory	LA-OPHL
	All	Any CRAB isolates that are <u>resistant</u> to all drugs tested by submitting laboratory	LA-OPHL
<i>Staphylococcus aureus</i> , Vancomycin Intermediate or Resistant (VISA/VRSA)	All	<i>Staphylococcus aureus</i> when vancomycin MIC ≥ 8 µg/ml	LA-OPHL

¹ Minimum inhibitory concentrations of ≥4 µg/mL for doripenem, imipenem or meropenem or ≥2 µg/mL for ertapenem

² Sterile body sites include blood, cerebrospinal fluid (CSF), pleural fluid, peritoneal fluid, pericardial fluid, joint fluid, bone, organs

³ Minimum inhibitory concentrations of ≥8 µg/mL for imipenem, meropenem, or doripenem

Submission Guidelines to LA-OPHL in Baton Rouge	Submission Guidelines to Southeast Antimicrobial Resistance Laboratory Network (ARLN) in Tennessee
<p>Submit the isolate on a slant to the LA-OPHL.</p> <ul style="list-style-type: none"> • Include a copy of the original antibiotic susceptibility report. • Attach an accompanying Lab Form 93 with the submission: https://ldh.la.gov/assets/oph/Center-PHCH/Center-CH/lab/LabForms/LabForm93.pdf. <ul style="list-style-type: none"> ◆ Note that two unique identifiers are required for specimen submissions (e.g., patient name and medical record number; date of birth is not a unique identifier). ◆ When completing the Lab Form 93, select “Other” for the test requested and specify “CRO Confirmation” and the suspected organism identified as appropriate. 	<p>Notify the HAI/AR program as well as the Southeast AR Laboratory by sending an e-mail notification to hai@la.gov and arln.health@tn.gov.</p> <ul style="list-style-type: none"> • Attach the antibiotic susceptibility report <u>and</u> a facesheet/demographics page for the patient. • Ensure the specimen source is noted. <p>The HAI/AR team will respond if the isolate is approved for testing and will send shipment instructions.</p> <ul style="list-style-type: none"> • A FedEx account number will be shared with facilities that are approved for isolate submissions. • Isolates should only be shipped Monday through Thursday unless special approval is communicated by ARLN. • Note: submitters should list the <i>submitting facility</i> as the submitter, not LA-OPHL. <p>Results will be sent to submitting facilities by snail mail.</p>